Introduction
Stent thrombosis (ST) is a rare but devastating complication following coronary stent implantation as it may lead to death or myocardial infarction (MI) in up to 90% of cases. [1] [2] [3] Whereas early (0-30 days) and late (31-360 days) ST occur with similar frequency among patients treated with bare metal (BMS) and early generation drug-eluting stents (DES), 4-6 very late ST (VLST) emerged as a distinct entity complicating the use of early generation DES releasing sirolimus (SES) or paclitaxel (PES) with a steady annual risk of 0.5-0.6% up to five years. 7, 8 Mechanisms leading to VLST are distinct from those responsible for early or late ST.
The persistence of uncovered struts with evidence of chronic inflammation and fibrin deposition leading to positive remodeling and strut malapposition were the hallmarks of thrombosed stent segments in post-mortem and intracoronary imaging studies. [7] [8] [9] [10] [11] The durable polymer matrix in conjunction with the dose of the antiproliferative drug and its release kinetics have been incriminated as a likely trigger of delayed healing and chronic inflammation leading to these late adverse events. 12, 13 Newer generation DES have been developed to improve the safety profile by means of more biocompatible polymers, reduced drug dose with adapted release kinetics and reduced strut thickness. A newer generation DES releasing everolimus (EES) has been shown to improve safety and efficacy compared with PES in several randomized clinical trials. 14, 15 Conversely, direct comparison of EES with SES up to one year yielded similar results in terms of safety and efficacy in several trials, [16] [17] [18] [19] [20] [21] including the synthesis of these results in a recently published meta-analysis. 22 So far, these studies were limited in size with maximal follow-up to only two years, and none of the studies specifically addressed the endpoint VLST in a large patient population with the unrestricted use of DES. The latter is important as VLST became apparent 
Data collection
All patients were actively followed for major adverse cardiac events using patientadministered postal questionnaires including questions on re-hospitalization and major adverse cardiac events. This was complemented by a search of hospital databases of the two institutions.
In Bern, the last follow-up took place from respectively. Vital status was ascertained from hospital records and municipal civil registries. For patients with a suspected event, relevant medical records, discharge letters, and coronary angiography documentation were systematically collected. All suspected clinical events were adjudicated by local cardiologists affiliated with the two institutions, whereas all ST events were adjudicated by an independent clinical event committee whose members were unaware of the type of stent implanted. Baseline clinical and procedural characteristics and all follow-up data were entered into a dedicated database, held at an academic clinical trials unit (CTU Bern, Bern University Hospital, Switzerland) responsible for central data audits and maintenance of the database.
and treatment including peri-and post-procedural medication regimen were performed according to current practice guidelines. All patients irrespective of stent type received a loading dose of clopidogrel 300mg to 600mg during or immediately after the procedure and were prescribed aspirin once daily lifelong. In the Dutch institution, clopidogrel was administered to patients with SES for at least 3 months, and for at least 6 months if patients had received 3 or more stents, the total stent length was >36mm, or a chronic total occlusion or bifurcation was treated. Dutch patients treated with PES received clopidogrel for at least 6 months, while EES patients were prescribed clopidogrel for 12 months. In the Swiss institution, all patients were prescribed clopidogrel for a duration of at least 12 months irrespective of stent type. The use of glycoprotein IIb/IIIa antagonists was left at the discretion of the operator.
Definitions
The primary endpoint was definite ST up to a maximum follow-up of four years. ST was defined according to the Academic Research Consortium (ARC) 24 and reported separately for the early (0-30 days), late (31-360 days) and very late (>360 days) time period. The definition of cardiac death included any death due to immediate cardiac cause, procedure related deaths, unwitnessed death and death of unknown cause. The diagnosis of MI was based on an elevation in CK to more than twice the upper limit of normal (ULN) and an elevation of CK-MB to more than three times ULN in the presence of ischemic symptoms or ischemic ECG changes. A 12-lead electrocardiogram was obtained prior to the procedure and within 24 hours after PCI.
Additional ECGs were obtained in case of recurrent signs or symptoms of ischemia. Risk factors and co-morbidities in each patient were determined as classified by the treating physician. Acute coronary syndrome was defined as acute myocardial ischaemia based on clinical symptoms, electrocardiographic changes, and elevation of cardiac biomarkers and encompasses an acute ST-7 segment (STEMI) and non-ST segment myocardial infarction (NSTEMI) and unstable angina.
Definitions of hypertension, hyperlipidaemia and renal dysfunction were previously reported.
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Statistical analysis
Baseline and procedural variables among the three stent types are presented as counts and percentages for dichotomous variables and as mean and standard deviation (SD) for continuous variables. The comparisons between groups among dichotomous variables were performed using
Pearson's chi square test and Student's t-test for continuous variables. We calculated incidence rates (IR) per 100 patient years (PY): the number of new events occurring during a specific time period divided by the total number of patient years actually observed. In contrast to crude percentages, IR take into account differences in the follow-up duration between stent types.
Univariable and multivariable Cox proportional hazard regression models were used to assess hazard ratios with 95% confidence intervals (CI) for comparing each of the early generation DES to EES. For each center, we estimated propensity scores for receiving EES using a logit model including age, gender and pre-treatment variables associated with stent selection at p<0.10:
family history of coronary artery disease, acute coronary syndrome and cardiogenic shock for both centres; BMI and left ventricular ejection fraction as additional variables for Bern; arterial hypertension, smoking, diabetes and hyperlipidaemia for Rotterdam. Propensity scores were used to derive inverse probability of treatment weights, with the inverse of the propensity score as analytical weights in EES patients and the inverse of 1 minus the propensity score in early generation drug eluting stent patients. Comparisons between stents were performed using a Cox proportional hazards model, crude and adjusted using inverse probability of treatment weighting.
Then, we used landmark analyses according to a pre-specified landmark point at 1 year (360 days) and estimated hazard ratios and cumulative incidence rates separately for events up to one 
Stent thrombosis
Crude and adjusted outcomes for the primary endpoint ARC definite ST and ARC definite or probable ST are shown in Table 3 and Figure 2 
Death and myocardial infarction
Crude and adjusted outcomes of major ischemic endpoints including death, cardiac death and MI are summarized in Table 4 . In crude analyses, the risk of cardiac death was lowest with Table 1 , Figure   5B ). Formal test for differences in log hazard ratios of the composite outcome of cardiac death or MI between outcome events associated with definite ST and outcome events not associated with definite ST were positive for both, crude and adjusted analyses (p for difference 0.01, see
Supplemental Table 1 ). We observed no difference between stent types and the risk of cardiac death irrespective of the association with or without definite ST.
Cardiovascular medications at baseline and at latest follow-up are shown in Supplemental Table 2 Table 4 ).
Discussion
In this large, observational cohort study of all-comers patients treated with the unrestricted use of DES followed for up to 4 years, newer generation EES reduced the overall risk of ARC definite ST by 58% compared with early generation SES and by 68% compared with PES. The benefit in favor of EES was most pronounced during the very late period (> 1 year) with a 67% and 76% reduced risk of definite ST compared with SES and PES, respectively, resulting in an important reduction of the risk of very late ST with the use of EES.
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Our findings are consistent with the two year outcomes of the randomized COMPARE trial comparing newer generation EES with early generation PES in an all-comers patient population. 25 Compared with PES, the overall risk of definite ST was lowered by 63% with the use of EES, whereas the risk of VLST was lowered by 77% between 1 and 2 years of follow-up.
In the randomized SPIRIT IV trial comparing EES with PES, the overall risk of definite ST at 2 years was also lowered by 64% in favor of EES, whereas the risk of VLST was non-significantly reduced by 24% during the very late period (> 1 year). 26 The latter observation is most likely related to differences in patient populations, as the phenomenon of VLST emerged among more complex patients and lesions. Although the duration of dual antiplatelet therapy was longer in SPIRIT IV compared with COMPARE and may have influenced outcomes, it remains to be shown whether prolonged dual antiplatelet therapy effectively prevents VLST. The present study substantially adds to the available evidence of the risk of VLST with newer generation DES by extending the follow-up observation to 4 years in the largest patient population treated with EES so far. As all consecutive patients treated with either EES, SES, or PES were included into the present study, this cohort provides a high degree of generalizability to routine clinical practice in experienced centres. Moreover, our study is not limited to the comparison of EES with PES, but also provides long-term evidence for the comparison between EES and SES, demonstrating a similar reduction in the risk of overall ST and VLST in favor of EES. Available evidence from randomized trials comparing EES with SES is still limited and based on one-year data. In a recent meta-analysis of data up to one year, however, de Waha et al reported on the composite of definite or probable ST and found a 22% relative risk reduction, even though confidence intervals were wide and overlapped the line of no difference. 22 These mid term results are in line with our long-term results on the same outcome, with a 22% relative risk reduction (95% 0.63 to 0.95). The robustness of the present analysis is further substantiated by the consistent findings in stratified analyses across major subgroups for the comparison of EES with SES and PES.
While early generation SES and PES showed the well established ongoing risk of VLST with an annual rate of 0.6 to 0.7%, the risk of VLST associated with EES in the present study was comparable with published long-term data on BMS through 4 years. 6 The reduction of VLST is particularly important as the increased risk of VLST with early generation DES stirred a debate regarding the need of prolonged dual antiplatelet therapy. 27 Due to the low rate of VLST strut thickness may result in less arterial injury, may accelerate re-endothelialisation due to the lower physical height of the mechanical barrier, and a lesser degree of flow disruption resulting in a lower thrombogenicity. 30, 31 Second, it has been suggested that the properties of the fluoropolymer surface (polyvinylidene fluoride-cohexafluoropropylene) reduce thrombogenicity and inflammatory reactions while improving endothelialisation. 32 Improved endothelialisation has been shown in a comparative study in rabbit iliac arteries showing more rapid reendothelialisation with EES compared with SES and PES at 14 days. 33 Third, drug dose and release kinetics may play a role as higher doses not only inhibit endothelialisation but may also cause toxic effects within the vessel wall. 34 A non-randomized study compared the in-vivo healing response between EES and SES using optical coherence tomography and reported a lower incidence of uncovered struts (EES 4.4% vs. 10.5%, p=0.016) as well as a lower rate of intracoronary masses compatible with thrombus (5.0 % vs. 34.3%, p<0.001).
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Alternative DES platforms -such as biodegradable polymer based DES and fully bioresorbable devices -have been developed in order to further improve upon the clinical safety and efficacy of percutaneous coronary intervention. Although it appears difficult to further improve outcomes in terms of VLST, remaining issues such as complex patient populations (diabetes, multivessel disease), lack of vasomotion and remodeling of the stented segment, side branch access, surgical revascularization of previously stented long segments and non-invasive imaging will need to be addressed by future generation devices.
Limitations
The present study has several limitations. This was not a randomized comparison between newer and early generation DES, and in fact we observed differences in baseline clinical and procedural characteristics between the three groups. However, analyses were adjusted for these differences using inverse probability of treatment weighting thus minimizing the potential of bias. Moreover, differences in favor of EES were large, consistent across major subgroups and plausible as it relates to the benefit in reducing the risk of cardiac death or MI for events associated with ST. The follow-up at four years is not complete in the EES and PES group, however a sensitivity analysis limited to patients with complete follow-up beyond 2 years (Supplemental Table 4 ) found the results to be even more in favor of EES suggesting an important differential in timing of individual adverse events (Supplemental Table 4 ). Another limitation is the sequential enrolment period for patients treated with EES compared with SES and PES. We used postal questionnaires to obtain information about possible events complemented by a search of the hospital database at both institutions, which may be considered as inferior compared to telephone follow-up or clinical visits. However, event rates observed with first generation DES were higher than in many randomized controlled trials or registries and in view of a similar methodology applied for all three stent groups, and underreporting of events appears to be unlikely. Differences in the duration of dual antiplatelet therapy within the first year following DES implantation may have contributed to an improved outcome in patients treated with EES. Although the prescription time was limited to one year in all EES patients, we cannot exclude, that a higher proportion of EES patients continued the dual antiplatelet therapy beyond one year and this may improved outcomes observed with EES. We however report the proportion of patients on DAPT at the latest follow-up and the proportion of patients on DAPT was comparable among the three stent types taking into account the different timepoint of the latest follow-up assessment when information about dual antiplatelet therapy was assessed controlled trials suggest that a prolongation of DAPT beyond 6 months or 1 year, respectively, does not improve on ischemic outcomes, suggesting that potential differences in DAPT beyond one year may not impact on the primary outcome measure ARC definite stent thrombosis. 28 29 We cannot exclude, that improvements in interventional treatment strategies over time such as higher implantation pressures, more frequently performed post-dilatation and thrombus aspiration may have contributed to an improved outcome among EES as compared to SES and PES treated patients. However, these potential improvements in interventional treatment technique are more likely to impact stent related outcomes within the first year following stent implantation rather than during the very late time period. are presented as mean (SD) or n (%). Comparisons between groups for dichotomous variables were performed using Pearson's chi square test and Student's t-test for continuous variables. Number of patients on discharge medication is based on the number of patients alive at discharge: EES= patients, SES= patients, PES patients. EES=everolimus-eluting stent, SES=sirolimus-eluting stent, PES=paclitaxel-eluting stent. Clinical outcome numbers are expressed as counts and incidence rates per 100 patient years. Crude hazard ratios were calculated using Cox proportional hazard models. Adjusted risk ratios were calculated using inverse probability of treatment weights as analytical weighting in Cox proportional hazards models stratified by center. EES=everolimus-eluting stent, SES=sirolimus-eluting stent, PES=paclitaxel-eluting stent, HR=hazard ratio, CI=confidence interval, ST=stent thrombosis. Clinical outcome numbers are expressed as counts and incidence rates per 100 patient years. Crude hazard ratios were calculated using Cox proportional hazard models. Adjusted risk ratios were calculated using inverse probability of treatment weights as analytical weighting in Cox proportional hazards models stratified by center. EES=everolimus-eluting stent, SES=sirolimus-eluting stent, PES=paclitaxel-eluting stent, HR=hazard ratio, CI=confidence interval, MI=myocardial infarction, yr=year, yrs=years. Table 1 . Confidence bars are indicated every 6 month.
Conclusions
Allocated to EES n = 4465
November Supplemental Tables Supplemental Table 1 . Unadjusted and adjusted hazard ratios and p--values for differences in log hazard ratios of the composite outcome of cardiac death or MI between outcome events associated with definite ST and outcome events not associated with definite ST. 
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